Paperpal Prime Logo

European Heart Journal - Cardiovascular Pharmacotherapy : Impact Factor & More

eISSN: 2055-6845pISSN: 2055-6837

Key Metrics

CiteScore
7.8
H-Index
35
Impact Factor
5 - 10
SJR
Q1Pharmacology (medical)
SNIP
1.61
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on European Heart Journal - Cardiovascular Pharmacotherapy

European Heart Journal - Cardiovascular Pharmacotherapy Journal Specifications

Overview
Publisher OXFORD UNIV PRESS
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year2015
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in European Heart Journal - Cardiovascular Pharmacotherapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in European Heart Journal - Cardiovascular Pharmacotherapy

May the Universal Truth rest in peace and us with Her? On how to understand inconsistency in and among pharmacological trials.
  • 5 Aug 2026
  • European heart journal. Cardiovascular pharmacotherapy
Authors' reply to: "Stent-Free Is Not Risk-Free: Risk-Defined DAPT After DCB-Only PCI in ACS".
  • 4 Aug 2026
  • European heart journal. Cardiovascular pharmacotherapy
Correction to: Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio-renal-metabolic risk modulation.
  • 28 Jul 2026
  • European heart journal. Cardiovascular pharmacotherapy
From "bridging specialties" to "owning the patient": rethinking accountability in Cardiovascular-Kidney-Metabolic syndrome care.
  • 27 Jul 2026
  • European heart journal. Cardiovascular pharmacotherapy
Beyond API-CAT: The remaining challenges of extended anticoagulation for cancer-associated thrombosis.
  • 22 Jul 2026
  • European heart journal. Cardiovascular pharmacotherapy
Reply to Zhang and Lou: beta-blockers after myocardial infarction should be guided by indication, ejection fraction, and contemporary evidence.
  • 17 Jul 2026
  • European heart journal. Cardiovascular pharmacotherapy
May the Universal Truth rest in peace and us with Her? On how to understand inconsistency in and among pharmacological trials.
  • 5 Aug 2026
  • European heart journal. Cardiovascular pharmacotherapy
Authors' reply to: "Stent-Free Is Not Risk-Free: Risk-Defined DAPT After DCB-Only PCI in ACS".
  • 4 Aug 2026
  • European heart journal. Cardiovascular pharmacotherapy
Correction to: Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio-renal-metabolic risk modulation.
  • 28 Jul 2026
  • European heart journal. Cardiovascular pharmacotherapy
From "bridging specialties" to "owning the patient": rethinking accountability in Cardiovascular-Kidney-Metabolic syndrome care.
  • 27 Jul 2026
  • European heart journal. Cardiovascular pharmacotherapy
Beyond API-CAT: The remaining challenges of extended anticoagulation for cancer-associated thrombosis.
  • 22 Jul 2026
  • European heart journal. Cardiovascular pharmacotherapy
Reply to Zhang and Lou: beta-blockers after myocardial infarction should be guided by indication, ejection fraction, and contemporary evidence.
  • 17 Jul 2026
  • European heart journal. Cardiovascular pharmacotherapy

FAQs on European Heart Journal - Cardiovascular Pharmacotherapy